William C. Fairey

William C. Fairey joined MyoKardia as Chief Commercial Officer and Executive Vice President in January 2019 with nearly three decades of biopharmaceutical industry experience building and leading patient-focused and science-driven organizations. Most recently, he served as the Chief Operating Officer and Executive Vice President of ChemoCentryx, Inc., where he led the company’s commercial strategy, including the development and execution of commercialization plans for avacopan and CCX140. Prior to ChemoCentryx, Mr. Fairey held global leadership positions with Actelion Pharmaceuticals over a period of seventeen years, most recently serving as President of Actelion Pharmaceuticals U.S. Inc., overseeing more than 400 employees and $1.5 billion in net sales in 2017 before its acquisition by Johnson & Johnson for $30 billion. At Actelion US, he helped the company gain FDA approvals and launch OPSUMIT and UPTRAVI for pulmonary arterial hypertension and VALCHLOR for cutaneous T-cell lymphoma. Mr. Fairey also served as President of Actelion Canada and as Regional Vice President of Australia Asia Pacific, where he had oversight across the region, including founding Actelion’s first affiliates in China, Taiwan and Singapore. Before taking on the Canadian role, Mr. Fairey was Vice President of Sales and Managed Markets in the US, where he built Actelion’s first sales and managed markets teams and established the strategies and systems to support the launch of Actelion’s first product, TRACLEER. Before joining Actelion, Mr. Fairey held a number of commercial roles during his 12 years with Parke-Davis Pharmaceuticals US.

Mr. Fairey holds a bachelor’s degree in Biology from the University of Oregon and earned a Master of Business Administration degree from Saint Mary’s College of California.